Cargando…
Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade
BACKGROUND: The benefit of induction chemotherapy in locally advanced oral squamous cell carcinoma (OSCC) remains to be clearly defined. Induction chemotherapy is likely to be effective for biologically distinct subgroups of patients and biomarker development might lead to identification of the pati...
Autores principales: | Zhu, Dong-wang, Liu, Ying, Yang, Xiao, Yang, Cheng-zhe, Ma, Jie, Yang, Xi, Qiao, Jin-ke, Wang, Li-zhen, Li, Jiang, Zhang, Chen-ping, Zhang, Zhi-yuan, Zhong, Lai-ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702430/ https://www.ncbi.nlm.nih.gov/pubmed/23786757 http://dx.doi.org/10.1186/1471-2407-13-301 |
Ejemplares similares
-
Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma
por: Shao, Yu-Yun, et al.
Publicado: (2022) -
Interplay of membrane crosslinking and curvature induction by annexins
por: Mularski, Anna, et al.
Publicado: (2022) -
Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis
por: Ma, Jie, et al.
Publicado: (2013) -
Do all patients with advanced N-stage nasopharyngeal carcinoma benefit from the addition of induction chemotherapy to concurrent chemoradiotherapy?
por: Yao, Ji-Jin, et al.
Publicado: (2019) -
Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome
por: Ju, Wu‐tong, et al.
Publicado: (2021)